• 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-02
  • 2021-03
  • 2020-08
  • 2020-07
  • 2020-03
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • br Appendix A Supplementary data br References


    Appendix A. Supplementary data
    [4] Niedhammer I, Bugel I, Bonenfant S, Goldberg M, Leclerc A. Validity of self-reported weight and height in the French GAZEL cohort. Int J Obes Relat Metab Disord : J Int Assoc Study Obesity 2000;24(9):1111e8.
    [6] Villanueva EV. The validity of self-reported weight in US adults: a population based cross-sectional study. BMC Publ Health 2001;1:11. [7] Strassmann G, Fong M, Kenney JS, Jacob CO. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 1992;89(5): 1681e4.
    [8] Martignoni ME, Kunze P, Hildebrandt W, Kunzli B, Berberat P, Giese T, Kloters O, Hammer J, Buchler MW, Giese NA, et al. Role of mononuclear GW3965 and inflammatory cytokines in pancreatic cancer-related cachexia. Clin Canc
    [9] Okada S, Okusaka T, Ishii H, Kyogoku A, Yoshimori M, Kajimura N, Yamaguchi K, Kakizoe T. Elevated serum interleukin-6 levels in patients with pancreatic cancer. Jpn J Clin Oncol 1998;28(1):12e5. [10] Lerner L, Gyuris J, Nicoletti R, Gifford J, Krieger B, Jatoi A. Growth differenti-ating factor-15 (GDF-15): a potential biomarker and therapeutic target for cancer-associated weight loss. Oncol Lett 2016;12(5):4219e23.
    [11] Miura T, Mitsunaga S, Ikeda M, Shimizu S, Ohno I, Takahashi H, Furuse J, Inagaki M, Higashi S, Kato H, et al. Characterization of patients with advanced pancreatic cancer and high serum interleukin-6 levels. Pancreas 2015;44(5): 756e63.
    [12] Farren MR, Mace TA, Geyer S, Mikhail S, Wu C, Ciombor K, Tahiri S, Ahn D, Noonan AM, Villalona-Calero M, et al. Systemic immune activity predicts overall survival in treatment-naive patients with metastatic pancreatic can-cer. Clin Canc Res : Official J Am Assoc Canc Res 2016;22(10):2565e74.
    [14] Yako YY, Brand M, Smith M, Kruger D. Inflammatory cytokines and angiogenic factors as potential biomarkers in South African pancreatic ductal adenocar-cinoma patients: a continuous variation preliminary report. Pancreatology : Official J Int Assoc Pancreatol (IAP) 2017;17(3):438e44.
    [15] Talar-Wojnarowska R, Gasiorowska A, Smolarz B, Romanowicz-Makowska H, Kulig A, Malecka-Panas E. Clinical significance of interleukin-6 (IL-6) gene polymorphism and IL-6 serum level in pancreatic adenocarcinoma and chronic pancreatitis. Dig Dis Sci 2009;54(3):683e9. [16] Blogowski W, Deskur A, Budkowska M, Salata D, Madej-Michniewicz A, Dabkowski K, Dolegowska B, Starzynska T. Selected cytokines in patients with pancreatic cancer: a preliminary report. PloS One 2014;9(5):e97613. [17] Holmer R, Goumas FA, Waetzig GH, Rose-John S, Kalthoff H. Interleukin-6: a villain in the drama of pancreatic cancer development and progression. Hepatobiliary Pancreat Dis Int: HBPD INT 2014;13(4):371e80.  [18] Shaw VE, Lane B, Jenkinson C, Cox T, Greenhalf W, Halloran CM, Tang J, Sutton R, Neoptolemos JP, Costello E. Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease. Mol Canc 2014;13:114.
    [19] Mace TA, Shakya R, Pitarresi JR, Swanson B, McQuinn CW, Loftus S, Nordquist E, Cruz-Monserrate Z, Yu L, Young G, et al. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Gut 2018;67(2):320e32.
    [20] Goumas FA, Holmer R, Egberts JH, Gontarewicz A, Heneweer C, Geisen U, Hauser C, Mende MM, Legler K, Rocken C, et al. Inhibition of IL-6 signaling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models of pancreatic cancer. Int J Canc 2015;137(5):1035e46. [21] Fogelman DR, Morris J, Xiao L, Hassan M, Vadhan S, Overman M, Javle S, Shroff R, Varadhachary G, Wolff R, et al. A predictive model of inflammatory markers and patient-reported symptoms for cachexia in newly diagnosed pancreatic cancer patients. Support Care Canc : Official J Multinatl Assoc Support Care Canc 2017;25(6):1809e17.